CSGEF yields 5.62% · PFE yields 6.13%● Live data
📍 CSGEF pulled ahead of the other in Year 1
Combined, CSGEF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSGEF + PFE for your $10,000?
China Suntien Green Energy Corporation Limited, together with its subsidiaries, develops and utilizes clean energy in Mainland China. It operates through three segments: Natural Gas, Wind Power and Solar Energy, and Other. The Natural Gas segment sells natural gas and gas appliances, as well as provides construction and connection services for natural gas pipelines. The Wind/Solar Power segment engages in the development, management, and operation of the wind farm and solar power plants; and generates and sells electric power for power grid companies. The Other segment engages in the management and property leasing business. As of December 31, 2021, the company owned 7 long-distance natural gas transmission pipelines, 20 high-pressure branch pipelines, 31 urban gas projects, 25 distribution stations, 19 gate stations, 6 compressed natural gas (CNG) primary filling stations, 3 CNG secondary filling stations, 3 liquefied natural gas filling station, and 2 L-CNG joint filling stations. It also had a wind power consolidated installed capacity of 5,673.85 megawatts (MW) and installed capacity under management of 5,869.45 MW, as well as an attributable installed capacity of 5,311.60 MW. It also engages in the provision of project investment, investment management, and technical development services; and investment and sale of solar energy appliances, as well as provides service consultancy services. Further, it offers operation and maintenance of photovoltaic power stations and logistics, loading and unloading, and transportation services. The company was incorporated in 2010 and is headquartered in Shijiazhuang, the People's Republic of China.
Full CSGEF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.